Novo Nordisk Inc. is recalling six batches of the GlucaGen HypoKit in the U.S. due to two customer complaints from the UK and Portugal involving…
Category: Injectable Medication
The U.S. FDA approved Sanofi’s new diabetes drug, Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels)…
The Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0, recommending the…
Todd Hobbs, the chief medical officer for North America at Novo Nordisk, knows diabetes from all angles: as a patient; as an endocrinologist (for ten years he ran a clinical practice focused on patients of all ages with diabetes); as an executive at a pharmaceutical company working to develop new treatments (he’s worked at Novo Nordisk since 2004); and as a parent (one of his six sons was diagnosed with type 1 at age five)
A yearlong clinical trial in more than a dozen countries reveals that once-a-week-Trulicity, used in conjunction with short acting insulin, not only improved blood sugar control for subjects with type 2 diabetes, but also curbed hypoglycemia compared to a standard treatment and reduced weight in trial subjects.
On Thursday the United States Food and Drug Administration approved Trulicity, by Eli Lilly and Company, a once weekly, injectable GLP-1 treatment for adults with Type 2 diabetes.
The change in thinking about the ways type 2 diabetes evolves indirectly opened the door to considering new ways of thinking about how type 1 diabetes behaves. That shift led to considering whether that door swung both ways and if type 1 diabetics might benefit from treatments designed to treat type 2 diabetes.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing…
The two GLP-1 treatments available are sold under the brand names Byetta and Victoza. The drugs, however, are not very popular with consumers, and are not nearly as popular as they deserve to be, according to Edelman. “It’s a case of clinical inertia on behalf of doctors,” Edelman says regarding one reason why more GLP-1 prescriptions aren’t being written.
IDegLira is a combination of Tresiba (insulin degludec), a once-daily basal insulin analogue with an ultra-long duration of action, and Victoza (liraglutide), the once-daily human GLP-1 analogue for the treatment of type 2 diabetes.